Saturday 17 October 2026
Export OABI’s income statement to Excel — free account
OmniAb, Inc.
OABI Healthcare Biotechnology
OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024. In the quarter to June 2026, revenue grew 244.2%, EPS grew 66.7% and free cash flow grew 211.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.59
0.14
−2.96%
Follow OABI
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 9.75 | 1.91 | 3.07 | 3.43 | 1.22 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 10.50 | 10.50 | 6.20 | 6.72 | 4.02 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 0 | 95 | 106 | 114 | 89 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.62 | 0.32 | 0.23 | 0.21 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 35 | 59 | 34 | 26 | 19 | ||||
| Gross margin, % | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 98.38 | |||||
| EBT | — | — | — | — | — | (34) | (26) | (64) | (71) | (66) | |||||
| EBT margin, % | — | — | — | — | — | (98.85) | (44.11) | (188.39) | (270.59) | (355.16) | |||||
| Net income | — | 0 | — | — | — | (27) | (22) | (51) | (62) | (65) | |||||
| Depreciation | — | — | — | — | — | 16 | 18 | 16 | 22 | 21 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.42 | 0.69 | 0.34 | 0.26 | 0.16 | ||||
| Earnings | — | — | — | — | — | (0.33) | (0.26) | (0.51) | (0.61) | (0.57) | |||||
| Cash flow | — | — | — | — | — | (0.07) | (0.04) | 0.02 | (0.39) | (0.32) | |||||
| Capex | — | — | — | — | — | (0.05) | (0.20) | (0.02) | (0.02) | 0.02 | |||||
| Free cash flow | — | — | — | — | — | (0.12) | (0.24) | 0.01 | (0.41) | (0.30) | |||||
| Book value | — | — | — | — | — | 2.84 | 4.00 | 3.16 | 2.81 | 2.35 | |||||
| Shares, m | — | — | — | — | — | 83 | 85 | 100 | 102 | 114 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | 0.00 | 5.01 | 18.24 | 13.73 | 11.26 | |||||
| P/B | — | — | — | — | — | 3.53 | 0.87 | 1.98 | 1.26 | 0.79 | |||||
| EV/Sales | — | — | — | — | — | 0.00 | 3.52 | 15.69 | 11.48 | 8.37 | |||||
| EV/FCF | — | — | — | — | — | (145.62) | (10.01) | 762.50 | (7.29) | (4.59) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (6) | (4) | 2 | (40) | (36) | ||||
| Capex | — | — | — | — | — | (4) | (17) | (2) | (2) | 2 | |||||
| Free cash flow | — | — | — | — | — | (10) | (21) | 1 | (42) | (34) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 2 | 99 | 72 | 53 | 49 | ||||
| Total debt | — | — | — | — | — | 14 | 26 | — | — | — | |||||
| Net debt | — | — | — | — | — | 0 | (88) | (87) | (59) | (54) | |||||
| Shareholders’ equity | — | — | — | — | — | 234 | 341 | 315 | 288 | 267 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (17.76) | (6.16) | (12.71) | (17.70) | (20.68) | ||||
| ROIC | — | — | — | — | — | (9.51) | (6.58) | (19.06) | (20.41) | (20.24) | |||||
| ROE | — | — | — | — | — | 0.00 | (7.76) | (15.43) | (20.60) | (23.36) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
OmniAb, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACHV Achieve Life Sciences, Inc. | $717.2M | — (loss-making) | — | +54.44% (above 0%: growing) | n/m | −19.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FDMT 4D Molecular Therapeutics, Inc. | $711.0M | — (loss-making) | — (loss-making) | +25,106.67% (above 0%: growing) | n/m | −61.28% (below 0%: shrinking) | 100.00% | (2,037.16%) | Compare |
| ANL Adlai Nortye Ltd. Sponsored ADR | $710.1M | — | — | — | — | +46.03% (above 0%: growing) | — | — | Compare |
| OABI OmniAb, Inc. | $687.7M | — (loss-making) | — (loss-making) | +244.24% (above 0%: growing) | n/m | +211.16% (above 0%: growing) | 95.45% | (49.47%) | |
| ANNX Annexon, Inc. | $682.5M | — (loss-making) | — | — | n/m | −26.41% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MDXG MiMedx Group, Inc | $682.2M | 111× | — (loss-making) | −34.73% (below 0%: shrinking) | n/m | −174.83% (below 0%: shrinking) | 68.96% | (28.69%) | Compare |
| CADL Candel Therapeutics, Inc. | $681.8M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PHAR Pharming Group N.V. Sponsored ADR | $681.6M | 62.4× | — (loss-making) | −3.22% (below 0%: shrinking) | −57.14% (below 0%: shrinking) | −183.87% (below 0%: shrinking) | 83.92% | 1.44% | Compare |
| GYRE Gyre Therapeutics, Inc. | $678.6M | — (loss-making) | — (loss-making) | −2.12% (below 0%: shrinking) | n/m | −130.45% (below 0%: shrinking) | 92.41% | (49.35%) | Compare |
| Median of peers | $682.3M | — | — | −1.06% | — | −77.31% | 68.96% | 0.00% |
OmniAb, Inc. (OABI) key facts
- Concern: OmniAb, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.7 million, down 29.3% from fiscal 2024.
- OmniAb, Inc. (OABI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, OABI traded at $4.59, a market capitalization of $687.7 million.
- Return on equity was −23.4% and debt-to-equity 0.00.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 2.45 (grey zone) for fiscal 2025.